Advancing excellence in laboratory medicine for better healthcare worldwide

Metabolomics (WG-M)



Name Position Country Term Time in Office
E. Fux Chair DE 1st 2021 10 - 2023 12
A. Bendt Member SG    
D. Di Natale  Member IT    
D. Friedecky Member CZ    
J. Ivanisevic Member CH    
J. Otvos Member US    

Terms of Reference 


  1. Assess Metabolomics approaches and Identify barriers/ challenges for clinical applications .
  2. Recommend solutions to facilitate the translation from academic laboratories to clinical laboratories




  1. To evaluate and monitor emerging trends of Research in the field of Metabolomics.
  2. To provide an overview on metabolite discovery strategies by combining metabolomics with orthogonal experimental and computational biology approaches.
  3. To assess the applications of Metabolomics in clinical diagnosis and prognosis.
  4. To develop periodic updates of the applications on Metabolomics technologies and methods in clinical diagnosis.
  5. To assess the accessibility and the barriers to routine implementation of Metabolomics in clinical laboratories.
  6. To develop a resource that will inform the IFCC community on developments in the applications of Metabolomics in Clinical Diagnosis /Prognosis as well as methods/technologies in the IVD Market.


List of Corresponding Members, nominated by National Societies

Name Full or Affiliate Member Societies
Etienne Cavalier Royal Belgian Society of Laboratory Medicine (RBSML) 
Qing Li Chinese Society of Laboratory Medicine (CSLM)
Marie Lenski Société Française de Biologie Clinique (SFBC)


Working Group Chair contacts:

Dr. Elie Fux
Group Head Analytics - Early Development
Roche Diagnostics Penzberg - Germany

Website developed by Insoft